<?xml version="1.0" encoding="UTF-8"?>
<ref id="B58-antibiotics-10-00092">
 <label>58.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Chang</surname>
    <given-names>H.C.</given-names>
   </name>
   <name>
    <surname>Huang</surname>
    <given-names>Y.T.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>C.S.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>Y.W.</given-names>
   </name>
   <name>
    <surname>Huang</surname>
    <given-names>Y.T.</given-names>
   </name>
   <name>
    <surname>Su</surname>
    <given-names>J.C.</given-names>
   </name>
   <name>
    <surname>Teng</surname>
    <given-names>L.J.</given-names>
   </name>
   <name>
    <surname>Shiau</surname>
    <given-names>C.W.</given-names>
   </name>
   <name>
    <surname>Chiu</surname>
    <given-names>H.C.</given-names>
   </name>
  </person-group>
  <article-title>
   <italic>In vitro</italic> and 
   <italic>in vivo</italic> activity of a novel sorafenib derivative SC5005 against MRSA
  </article-title>
  <source>J. Antimicrob. Chemother.</source>
  <year>2016</year>
  <volume>71</volume>
  <fpage>449</fpage>
  <lpage>459</lpage>
  <pub-id pub-id-type="doi">10.1093/jac/dkv367</pub-id>
  <pub-id pub-id-type="pmid">26553845</pub-id>
 </element-citation>
</ref>
